Embolic protection devices are generally used during percutaneous cardiac procedures. The use of embolic protection devices or EPD during percutaneous cardiac procedures has helped in reducing the number of complications, owing to debris being released into the bloodstream and causing blockages in smaller vessels. The devices are designed to capture and remove debris that may be extricated during procedures. Embolic protection devices capture the luminal and blood debris within saphenous vein grafts, during stenting, thus, preventing the distal embolization. These devices are usually considered an important part of the most reliable and evidence-based procedure for reducing per procedural myocardial infarction and other major cardiovascular events.
This procedure is always accompanied by imaging systems to ensure proper placement of the device. The three classes of embolic protection devices are distal occlusion devices, proximal occlusion devices, and Distal filters. Recently, in April 2018 an emerging medical device company named Emboline Inc. (CardioLogical Solutions which is the parent organization) announced that the company has completed a Series B funding round for its total embolic protection device for Trans Catheter Aortic Valve Replacement, also known as TAVR procedures, totaling over $10 million. The $10 million funding includes $3 million in new equity financing from multiple investors and $7 million in the conversion of previously-issued convertible notes.
One such device is WIRION, which is an embolic protection system comprised of an independent filter unit that can be delivered and deployed on any commercially marketed guide wires, as per the physician preference, anywhere on the wire, in minimally invasive interventional procedures.
The carotid artery diseases are expected to contribute to the overall embolic protection devices market, owing to the increase in the count of carotid artery stenting procedures and treatments. The adoption of minimally invasive procedures has also led to the popularity of carotid artery stenting over carotid endarterectomy. Increasing prevalence of cardiovascular diseases globally, and product penetration by local players, offering devices at lower average prices owing to a reduction in transportation cost is likely to boost the market. Moreover, increasing demand for minimally invasive procedures is also likely to boost the market demand for global embolic protection devices market.
However, certain limitations associated with each of the product types and group purchasing policies of large chain hospitals impose pricing pressures on manufacturers. This factor is likely to restrain the embolic protection devices market during the forecast period. Also, the use of embolic protection devices requires skilled expertise and knowledge; however, the lack of proficient personnel in the emerging economies is expected to hamper the future market growth.
The occlusion devices market is bifurcated on the following bases:
• Proximal Occlusion Devices
• Distal Occlusion Devices
• Distal Filter Devices
• Neurovascular Diseases
• Cardiovascular Diseases
• Peripheral Diseases
• Transcatheter Aortic Valve Replacement
• Carotid Artery Diseases Saphenous Vein Graft Disease
• Percutaneous Coronary Intervention
Geographically, the global occlusion devices market is divided into North America, Europe, Asia Pacific, and Latin America, Middle East and Africa. North America is attributed to have the significant share in the market with countries like U.S and Canada, owing to presence of well-equipped advanced devices and global market leaders such as Avinger, Boston Scientific Corporation, Abbott, and others. Europe market is expected to share the same potential with the countries like Germany, France, U.K, Spain, Italy, and others.
An upsurge in the prevalence of neurovascular, cardiovascular diseases in several countries across Asia Pacific such as India, Japan, China, Russia, Pakistan, and others is attributed to boost the global embolic protection devices market. LAMEA market is also attributed to grow in the upcoming years with the emerging countries.
The global key manufacturers of embolic protection devices market are:
• Abbott. (U.S)
• Avinger (U.S)
• Medtronic (Ireland)
• W. L. Gore & Associates (U.S)
• Allium Medical Solutions Ltd. (Israel)
• Edwards Lifesciences Corporation (U.S)
• Boston Scientific Corporation (U.S)
• Allium Medical Solutions (U.S)
• Claret Medical, Inc (U.S)
• Angioslide (U.S)